Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.945 – $1.02
Volume33,435
Market cap$19M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$18.88M
Price / earnings
—
Price / book
18.08×
Price / sales
57.21×
EV / sales
50.63×
EV / EBITDA
-1.66×
Profitability
Earnings per share
-$0.52
Return on assets
-213.77%
Return on equity
-951.92%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.24×
Quick ratio
1.24×
Cash ratio
0.83×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.97M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for COCP, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$105K
$225K
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$105K
$225K
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.15M
$1.21M
$862K
$1.14M
$986K
$981K
$1.19M
$1.8M
Research and development
$2.14M
$1.37M
$1.62M
$954K
$1.12M
$1.36M
$2.04M
$3.24M
Total operating expenses
$3.29M
$2.58M
$2.48M
$2.09M
$2.11M
$2.34M
$3.23M
$5.04M
Operating income
-$3.18M
-$2.36M
-$2.48M
-$2.09M
-$2.11M
-$2.34M
-$3.23M
-$5.04M
Interest expense
$10K
$22K
$47K
$22K
$28K
$37K
$55K
$111K
Income before taxes
-$3.16M
-$2.3M
-$2.43M
-$2.05M
-$2.06M
-$2.3M
-$3.27M
-$4.94M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.16M
-$2.3M
-$2.43M
-$2.05M
-$2.06M
-$2.3M
-$3.27M
-$4.94M
Net income attributable to common shareholders
-$3.16M
-$2.3M
-$2.43M
-$2.05M
-$2.06M
-$2.3M
-$3.27M
-$4.94M
EBITDA
-$3.17M
-$2.34M
-$2.47M
-$2.08M
-$2.09M
-$2.32M
-$3.2M
-$5.01M
Basic earnings per share
-$0.23
-$0.17
-$0.18
-$0.19
-$0.20
-$0.23
-$0.32
-$0.49
Diluted earnings per share
-$0.23
-$0.17
-$0.18
-$0.19
-$0.20
-$0.23
-$0.32
-$0.49
Recent news
Company coverage with links to the original publishers.
Cocrystal Pharma announced completion of dosing in its Phase 1b challenge study for CDI-988, an oral antiviral candidate for norovirus prevention and treatment, with no serious adverse events reported. The company received a $5 million private placement investment from OPKO Health and appointed antiviral development expert Carol Brosgart, MD to its Board. Preliminary efficacy results are expected near the end of 2026.
Cocrystal Pharma completed enrollment in the first cohort of a Phase 1b challenge study for CDI-988, an oral protease inhibitor for norovirus prevention and treatment. The company received FDA Fast Track designation for CDI-988 and an initial $225,000 NIH SBIR grant for influenza A/B antiviral development. Q1 2026 revenue was $225,000 from grant income, with net loss of $2.3 million and cash position of $4.7 million.
Cocrystal Pharma announced that its oral norovirus protease inhibitor CDI-988 will be presented at the ICAR 2026 conference in Prague. The company will present Phase 1 data and updates from an ongoing Phase 1b challenge study at Emory University School of Medicine. CDI-988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infections, with no approved antiviral therapies or vaccines currently available for this indication.
Cocrystal Pharma presented CDI-988, a potential first oral antiviral for norovirus infection, at the International Calicivirus Conference. The drug shows promising broad-spectrum activity and has received FDA clearance for a Phase 1b human challenge study.
Cocrystal Pharma's CFO and co-CEO James Martin will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference, discussing their clinical-stage antiviral drug development efforts.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.